Everence Capital Management’s Pacira BioSciences PCRX Stock Holding History

Everence Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8,940	Closed	-$235	–	799
2024 Q2	$235	Hold	8,940	–	–	0.02%	627
2024 Q1	$261	Hold	8,940	–	–	0.02%	614
2023 Q4	$302K	Hold	8,940	–	–	0.02%	561
2023 Q3	$274	Buy	8,940 +2,830	+46%	+$102K	0.02%	574
2023 Q2	$232K	Hold	6,110	–	–	0.02%	602
2023 Q1	$249	Hold	6,110	–	–	0.02%	607
2022 Q4	$236	Hold	6,110	–	–	0.02%	627
2022 Q3	$325K	Buy	6,110 +2,080	+52%	+$116K	0.03%	486
2022 Q2	$235K	Hold	4,030	–	–	0.02%	592
2022 Q1	$308K	Buy	+4,030	New	+$269K	0.02%	550
2021 Q3	–	Sell	-4,700	Closed	-$285K	–	757
2021 Q2	$285K	Hold	4,700	–	–	0.02%	580
2021 Q1	$329K	Buy	+4,700	New	+$336K	0.03%	519
2020 Q3	–	Sell	-6,900	Closed	-$303K	–	728
2020 Q2	$303K	Hold	6,900	–	–	0.04%	453
2020 Q1	$231K	Hold	6,900	–	–	0.03%	467
2019 Q4	$313K	Buy	+6,900	New	+$293K	0.05%	469

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Everence Capital Management's PCRX Position: Q3 2024 in Review

Everence Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 8,940 shares — an estimated $235 sold.

Everence Capital Management first reported a position in PCRX in Q4 2019 and held it in 15 quarters. The position peaked at $329K in Q1 2021. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

Everence Capital Management reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
Everence Capital Management sold 8,940 Pacira BioSciences shares in Q3 2024, an estimated $235.
Everence Capital Management first reported a position in Pacira BioSciences in Q4 2019 and held it in 15 quarters.
Everence Capital Management's Pacira BioSciences position peaked at $329K in Q1 2021.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Everence Capital Management's 13F filing for Q3 2024, filed 21 Oct 2024.